Join
Live feed
·
PRReleasevia Quantisnow
Aclaris Therapeutics Inc. logo

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
ACRS· Aclaris Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRS (Aclaris Therapeutics Inc.) and more on Quantisnow.